The popularity of Sildenafil initially drove a period of growth for pharma, however recent shifts present a uncertain outlook for shareholders. Off-patent alternatives are reducing earnings, and persistent litigation https://asiyauybl779514.shotblogs.com/sildenafil-and-big-pharma-a-precarious-play-55291951